ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

A CASE/CONTROL STUDY ON RAISED ANTI-THYROID PEROXIDASE ANTIBODY IN CASES OF HYPOTHYROIDISM AND EUTHYROIDS

AUTHORS:

Dr. Abdul Sadiq, Dr. Syed Ehsanullah, Dr. Zahid Ali

ABSTRACT:

Objective: To assess the raised level of anti-thyroid peroxidase antibody in patients of hypothyroidism and euthyroids. Material and methods: This case/control study was conducted at Department of Biochemistry BUMHS, Bolan Medical Complex Hospital, Quetta from January 2018 to June 2018 over the period of 6 months. Total 69 patients of hypothyroidism (as per operational definition) having age 18-60 years either male or female were selected. Age and sex matched euthyroids (FT3, FT4 and TSH within normal range) as described in operational definition was served as controls. Anti-thyroid peroxidase antibody assessed between the cases of controls. Results: A total of 138 cases fulfilling the inclusion/exclusion criteria were enrolled to compare the frequency of raised level of anti-thyroid peroxidase antibody in patients of hypothyroidism and euthyroids. Comparison of raised anti-thyroid peroxidase antibodies in both groups was done which reveals that Raised Anti-Thyroid Peroxidase Antibodies were recorded in 28.99%(n=20) in Group-A and 7.25%(n=5) in Group-B while 71.01%(n=49) in Group-A and 92.75%(n=64) in Group-B had no findings of Raised Anti-thyroid Peroxidase Antibodies, p value was calculated as 0.000 which shows a significant difference between the two groups. Conclusion: We concluded positive relationship of the presence of TPOAbs with levels of TSH and showed that TPOAbs and TSH predict future development of hypothyroidism. These results are consistent with the presence of TPOAbs necessitating a compensatory increase in levels of TSH for maintenance of euthyroidism, even in the euthyroid range. Keywords: Hypothyroidism, Euthyroids, Anti-thyroid peroxidase antibody.

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.